Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, UroGen Pharma Ltd’s stock clocked out at $10.39, up 4.63% from its previous closing price of $9.93. In other words, the price has increased by $4.63 from its previous closing price. On the day, 0.66 million shares were traded. URGN stock price reached its highest trading level at $10.96 during the session, while it also had its lowest trading level at $10.345.
Ratios:
To gain a deeper understanding of URGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.77 and its Current Ratio is at 9.00. In the meantime, Its Debt-to-Equity ratio is 4.81 whereas as Long-Term Debt/Eq ratio is at 4.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on August 22, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On February 08, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $35 to $10.
On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.Berenberg initiated its Buy rating on April 27, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 09 ’24 when Schoenberg Mark sold 859 shares for $13.08 per share. The transaction valued at 11,236 led to the insider holds 145,091 shares of the business.
Smith Jason Drew sold 1,521 shares of URGN for $19,895 on Sep 09 ’24. The General Counsel now owns 25,226 shares after completing the transaction at $13.08 per share. On Sep 09 ’24, another insider, Schoenberg Mark, who serves as the Officer of the company, bought 859 shares for $13.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 438451776 and an Enterprise Value of 311622912. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.91 while its Price-to-Book (P/B) ratio in mrq is 17.18. Its current Enterprise Value per Revenue stands at 3.487 whereas that against EBITDA is -3.742.
Stock Price History:
The Beta on a monthly basis for URGN is 1.09, which has changed by -0.30413455 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $20.70, while it has fallen to a 52-week low of $9.78. The 50-Day Moving Average of the stock is -9.85%, while the 200-Day Moving Average is calculated to be -23.27%.
Shares Statistics:
It appears that URGN traded 478.92K shares on average per day over the past three months and 477550 shares per day over the past ten days. A total of 42.19M shares are outstanding, with a floating share count of 36.53M. Insiders hold about 13.44% of the company’s shares, while institutions hold 89.35% stake in the company. Shares short for URGN as of 1735603200 were 5827536 with a Short Ratio of 12.17, compared to 1732838400 on 5773140. Therefore, it implies a Short% of Shares Outstanding of 5827536 and a Short% of Float of 14.140001.
